Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BMY 28090

Known as: BMY-28090, BMY28090 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryBMY-28090 is a novel actinomycete fermentation derived antitumor agent. The cytotoxic effect of BMY-28090 was evaluated in… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2004
2004
Elsamitrucin (BMY-28090) a novel fermentation product has demonstrated pre-clinical anti-tumour activity against a number of cell… Expand
  • table 1
Is this relevant?
1996
1996
SummaryPurpose: To determine the response rate of patients withrefractory/relapsed non-Hodgkin's lymphoma to treatment with… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
1993
1993
The cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human… Expand
Is this relevant?
1992
1992
Elsamitrucin (BMY-28090) is an antitumor antibiotic first described in 1985 that has significant oncolytic activity against a… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
1989
1989
SummaryThe compound BMY-28090 (elsamicin A) is a new fermentation product with antitumor properties, which has the same aglycone… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?